Draxis Health Inc.

Draxis Health Inc.

March 29, 2005 09:00 ET

DRAXIS Health to Present at The CIBC World Markets Specialty Pharmaceuticals Conference


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: DRAXIS HEALTH INC.

TSX SYMBOL: DAX
NASDAQ SYMBOL: DRAX

MARCH 29, 2005 - 09:00 ET

DRAXIS Health to Present at The CIBC World Markets
Specialty Pharmaceuticals Conference

MISSISSAUGA, ONTARIO--(CCNMatthews - March 29, 2005) - DRAXIS Health
Inc. (TSX:DAX)(NASDAQ:DRAX) announced today that Dr. Martin Barkin,
President and Chief Executive Officer of DRAXIS Health Inc. will present
at the annual CIBC World Markets Biotechnology & Specialty
Pharmaceuticals Conference on Monday, April 4, 2005 at 2:45 pm ET at the
Millennium Broadway Hotel, New York City.

Dr. Barkin will provide an overview of DRAXIS and discuss how the
Company is using its expertise and specialized facilities to pursue
growth opportunities in contract manufacturing, particularly sterile and
lyophilized products. He will also address the Company's pipeline of
innovative radiopharmaceutical products for molecular imaging.

Live Audio Web Cast

Members of the financial community, the media and other interested
parties can access a live webcast of the presentation on the DRAXIS
website at www.draxis.com and an archive of the webcast will be
available for 30 days following the conference.

About DRAXIS Health Inc.

DRAXIS Health is a rapidly growing specialty pharmaceutical company
providing products in three categories. Sterile products include liquid
and freeze-dried (lyophilized) injectables plus sterile ointments and
creams. Non-sterile products are produced as solid oral and semi-solid
dosage forms. Radiopharmaceuticals are used for both therapeutic and
diagnostic molecular imaging applications. Pharmaceutical contract
manufacturing services are provided through the DRAXIS Pharma division
and radiopharmaceuticals are developed, produced, and sold through the
DRAXIMAGE division. DRAXIS Health employs over 500 staff in its Montreal
facility.

For additional information please visit www.draxis.com.

This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements are not guarantees of future performance. By their nature,
forward-looking statements involve numerous assumptions, known and
unknown risks, uncertainties and other factors that may cause the actual
results or performance of the Company to be materially different from
such statements or from any future results or performance implied
thereby. Factors which could cause the Company's results or performance
to differ from current expectations include, but are not limited to,
timely regulatory approval of the Company's products; the ability to
comply with regulatory requirements applicable to the manufacture and
marketing of the Company's products; the Company's ability to obtain and
enforce effective patents; the non-infringement of third party patents
or proprietary rights by the Company and its products; the establishment
and maintenance of strategic collaborative and commercial relationships;
the Company's dependence on a small number of key customers; the
Company's ability to protect its confidential information; the
preservation of healthy working relationships with the Company's unions
and employees; the avoidance of product liability claims; and market
acceptance of the Company's products. For additional information with
respect to certain of these and other factors, reference should be made
to the Company's most recent Form 20-F filed with the United States
Securities and Exchange Commission, and its Annual Information Form
filed with the Canadian securities regulators. Unless otherwise required
by applicable securities laws, the Company disclaims any intention or
obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    DRAXIS Health Inc.
    Jerry Ormiston
    Investor Relations
    (877) 441-1984
    or
    The Investor Relations Group
    John Nesbett
    (212) 825-3210